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Chronic obstructive pulmonary disease (COPD) is caused by a1-antitrypsin deficiency (AATD)
genetic susceptibility and exacerbated by infection. The current pilot study aimed at studying
the combined effect of AATD and bacterial loads on the efficacy of COPD conventional phar-
macotherapy. Fifty-nine subjects (29 controls and 30 COPD patients) were tested for genetic
AATD and respiratory function. The bacterial loads were determined to the patients’ group
who were then given a long acting beta-agonist and corticosteroid inhaler for 6 months. Nine-
teen percent of the studied group were Pi*MZ (heterozygote deficiency variant), Pi*S (5%)
(milder deficiency variant), Pi*ZZ (10%) (the most common deficiency variant), and Pi*Mmal-
ton (2%) (very rare deficiency variant). The patients’ sputum contained from 0 to 8  108 CFU/
mL pathogenic bacteria. The forced vital capacity (FVC6) values of the AAT non-deficient
group significantly improved after 3 and 6 months. Patients lacking AATD and pathogenic bac-
teria showed significant improvement in forced expiratory volume (FEV1), FEV1/FVC6, FVC6,
and 6 min walk distance (6MWD) after 6 months. However, patients with AATD and patho-
genic bacteria showed only significant improvement in FEV1 and FEV1/FVC6. The findings
of this pilot study highlight for the first time the role of the combined AATD and pathogenic
bacterial loads on the efficacy of COPD treatment.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is defined as
the presence of irreversible or partially reversible airway
obstruction associated with chronic bronchitis and/or emphy-
sema [1]. The airflow limitation is usually both progressive and
associated with an abnormal inflammatory response of the
lungs to noxious particles or gases [2]. COPD is usually diag-
nosed in patients who have symptoms of cough, sputum pro-
duction, abnormal shortness of breath, dyspnea, or increased
forced expiratory time which improve by therapy [3,4]. The
presence of a post bronchodilator forced expiratory volume
(FEV1) < 80% of the predicted value in combination with
forced expiratory volume to forced vital capacity ratio
(FEV1/FVC) < 70% confirms the presence of airflow limita-
tion [3,5]. Emphysematous lung destruction is mainly due to
oxidative stress in addition to an imbalance of endogenous
proteinases and anti-proteinases in the lung; the imbalance
may be due to either genetic factors or inflammatory response
[6].
The discovery of the relation between a1-antitrypsin (AAT)
deficiency and the early onset of COPD suggested the role of
AAT in the pathogenesis of the disease [7]. Alpha 1-
antitrypsin inhibits protease enzymes and its deficiency leads
to protease/anti-protease imbalance, which breaks down the
connective tissue matrix of lung alveoli [8,9]. AAT is a single
chain protein consisting of 394 amino acids, where methionine
at position 358 acts as the active site [7,10]. Protease inhibitor
(Pi) gene, locus found on chromosome 14q32.1, encodes AAT
protein [11]. Mutations of Pi locus, now called SERPINA1,
lead to several variants: Pi*M (wild type), Pi*S, Pi*Z,
Pi*Mmalton and Q0Cairo [7,12–16]. The Pi*Z allele results
from the substitution of glutamic acid at position 342 by lysine
(Glu342Lys) [17] resulting in a severe deficiency in AAT levels.
The Pi*S allele results from the substitution of glutamic acid at
position 264 by valine (Glu264Val) [13] resulting in a mild to
moderate deficiency in AAT levels. However, the Pi*Mmaltonis characterized by the deletion of the entire codon encoding
the phenylalanine at position 52 (52Phedeleted) [16]. The
Q0Cairo is characterized by an A? T transversion resulting
in a premature stop codon (Lys259? Stop259) [12]. Both
Pi*Mmalton and Q0Cairo variants are very rare resulting in
deficiencies in AAT levels.
Bacterial infections cause exacerbations of COPD, resulting
in significant mortality and morbidity [18,19]. The pathogene-
sis of exacerbations is poorly understood, and the role of bac-
teria is highly controversial [19]. Beside the nature of the
bacterial species, bacterial load may also play an important
role in the airway inflammation in COPD patients [20].
COPD is becoming more prevalent in Western populations
and is set to explode in several developing countries such as
India, Mexico, Cuba, Egypt, South Africa and China [21].
Some recent studies tested the prevalence of COPD in the men-
tioned countries and found it to be 2–22% in India [22], 20.6%
in Mexico [23], 9.6% in Egypt [24], 4.1–24.8% in Sub-Saharan
Africa [25] and 8.2% in China [26]. Yet very little information
is known about the possible combined impact of AAT genetic
deficiency and the bacterial loads on COPD treatment, espe-
cially in developing countries such as Egypt. Accordingly,
the aim of this pilot study was to determine the genetic preva-
lence of AATD and its effect on the efficacy of COPD stan-
dard pharmacotherapy when combined with the effect of
bacterial loads, in a limited well-controlled sample of the
Egyptian population.
Subjects and methods
Study subjects
Thirty newly diagnosed COPD patients were recruited from
the outpatient clinics of Imbaba Chest Research, Allergy Insti-
tute, Kasr El-Aini Teaching Hospital, and El-Demerdash
Teaching Hospital within the Greater Cairo area. Informed
consent was obtained from all the study subjects. The study
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Research Ethics Committee, Faculty of Pharmacy, Cairo
University (protocol serial number: CL 403). The inclusion
criteria were as follows: patients newly diagnosed with COPD,
age between 18 and 65 years, and non-smoker or ex-smoker
(at least 6 months-smoke free period). Exclusion criteria were
the presence of cor pulmonale, stage 4 COPD, frequent COPD
exacerbations (>2 per year), any other organ affliction, and
active smoking history. Twenty-nine healthy subjects (non-
smoker or ex-smoker, age between 18 and 65 years with nor-
mal lung functions and no other respiratory conditions) were
recruited as matched controls.
Study design
This was a pilot, prospective, parallel, and controlled open-
label study that was divided into two phases: (i) identifying
the presence and the contribution of bacterial loads and
AATD allele in the development of COPD and (ii) monitoring
the response of the screened subjects to the COPD therapy.
Clinical assessment and medications
The COPD group received a treatment consisting of Symbi-
cort 320/9 turbohaler (AstraZeneca, Cairo, Egypt) (320
mcg budesonide and 9 mcg formoterol fumarate dihydrate)
to be used twice daily, and Vental metered dose inhaler
(ADCO, Cairo, Egypt) (100 mcg salbutamol/puff) to be used
when required for 180 days. All the medications were provided
to the patients on a monthly basis.
At baseline, all the subjects were screened for their demo-
graphic data, smoking habits, and medical and medication his-
tory. The patients’ monitoring parameters included the
following: respiratory function tests (pre and post bronchodi-
lation), arterial blood gases (ABG), pulse oximetry and six-
minute-walk distance test (6MWD). The patients were fol-
lowed up after 3 and 6 months.
Microbial loads determination
The sputum samples were collected at the beginning of the
study from the COPD group, where all the patients were asked
to spontaneously expectorate into a sterile plastic collection
cup. All of the sputum produced over a 10–15 min period
was collected. The sputum samples were obtained during the
first 4 h after rising that morning, kept cool, and then pro-
cessed within an hour of collection [20,27]. The sputum sam-
ples were screened for acceptability for microbiological
evaluation. Samples were accepted and further processed if
they contained less than 10 squamous epithelial cells (SEC)
per low-power field (LPF) and more than 25 polymorphonu-
clear neutrophils (PMNs) per LPF [28]. Sputum samples were
homogenized by mixing with an equal volume of 100 lg/mL
dithiothreitol (Fisher scientific, Loughborough, UK) [20].
Then, they were serially diluted in a phosphate-buffered saline
(prepared in laboratory), plated mainly on chocolate agar, and
incubated for 48 h at 37 C in 5% CO2 atmosphere [20]. Ali-
quots were also plated on 5% (v/v) blood agar (Oxoid), and
MacConkey agar (Oxoid) and incubated for 48 h at 37 C in
air [20]. Colonies were differentiated based on their morphol-
ogy; each type was counted and isolated. The isolated colonieswere stocked at – 70 C in 30% (v/v) glycerol (Sigma–Aldrich,
St. Louis, Missouri, USA) in brain heart infusion. The
bacterial isolates were then identified by matrix-assisted laser
desorption ionization time-of-flight mass spectrometry
(MALDI-TOF MS) using the MALDI Biotyper system (Bru-
ker Daltonics, Bremen, Germany) [29]. The counts for bacte-
rial species with a pathogenic potential to humans were
included in the bacterial loads, while those representing com-
mensals of the oral cavity were excluded.
Genotyping
Genomic DNA was extracted from peripheral blood (5 mL of
blood in EDTA anti-coagulant tubes) samples using the
Wizard Genomic DNA Purification Kit (Promega, Madison,
Wisconsin, USA). For the S variant (Pi*S), the method previ-
ously described was used [30]. Exon III, primers (IDT DNA,
Coralville, Iowa, USA) P3M (50-GAGGGGAAACTACAG
CACCTCG-30), and P3P (50-ACCCTCAGGTTGGGGAAT
CACC-30) were used to produce a 98-bp product that was sub-
sequently digested with TaqI restriction enzyme (NEB, Ips-
wich, Massachusetts, USA). DNA samples with the Pi*M
were cut into 78- and 20-bp bands, but the Pi*S remained as
a 98-bp band. While for the Z-variant (Pi*MZ, Pi*ZZ), the
previously described Hyp99I/amplified fragment length poly-
morphism (AFLP) method was adopted [31]. Exon V was
amplified using the primer pair (IDT DNA) 5M (50-GAGCC
TTGCTCGAGGCCTGGGATC-30), and 5P (50-CAGGAA
AACATGGGAGGGATTTAC-03). The amplicon (372 bp)
was digested by Hyp99I (NEB). Two fragments (286 and
86 bp) were obtained in the absence of the Pi*Z variant. How-
ever, if a sample was heterozygous for the Z variant (MZ) it
would be characterized by three bands (372, 286, and 86 bp),
and the presence of a 373 bp undigested would indicate that
the sample was homozygous for Pi*Z variant (ZZ). For
Pi*Mmalton detection, the mismatched restriction fragment
length polymorphism–polymerase chain reaction (RFLP–
PCR) assay previously described was used [14]. The primer
pair (IDT DNA) Mmalton-RFLP-Fw (50-ACACCAGTC
CAACAGCACCAATAAC-03), and Mmalton-RFLP-Rv (50-
TCTCCGTGAGGTTGAAATTCAGGCC-03) were used to
yield an amplicon of 134 bp. This product was further digested
using MboII restriction enzyme (NEB). The Pi*M allele was
expected to yield two bands (115 bp and 19 bp), while the
Pi*Mmalton allele remained as 134 bp product. Finally, for
the Pi*Q0Cairo, the primer pair (IDT DNA) P3 M (50-GAG
GGGAAACTACAGCACCTCG-30), and Q0Cairo-Rv (50-A
TGGCTAAGAGGTGTGGGCA-30) were used to amplify a
374 bp product from exon III. This was followed by direct
DNA sequencing [32].
Determination of AAT levels
Plasma was obtained from the collected blood samples as
described above. The samples were centrifuged at 2000g for
10 min at 4 C, and the supernatants were used as the plasma
sample. They were frozen at 70 C until further processing.
The AAT levels in plasma were determined using the alpha 1
Antitrypsin (SERPINA1) Human SimpleStep ELISATM
Kit (ab189579) (Abcam, Cambridge, UK) following the
manufacturer’s recommendations. Briefly, diluted plasma was
1022 M.G. Hennawy et al.incubated in wells that were pre-coated with an AAT specific
antibody. After washing, a biotinylated AAT antibody was
added followed by streptavidin–peroxidase conjugate. TMB
substrate was then added and the reaction was ended by the
addition of the stop solution. The color produced was mea-
sured immediately at wavelength 450 nm. The same proce-
dures were applied on standards provided in the kit to
construct a calibration curve that was then used to determine
the final AAT concentration in the assayed samples. Enzyme
inhibitor level 689 mg/dL was noted as severely deficient,
90–140 mg/dL was noted as mildly deficient, and P141 mg/
dL was noted as normal [33].
Statistical analysis
Statistical analysis was performed using the SPSS software
package version 20. Statistical significance was defined as a
P-value < 0.05. For continuous variables and nonparametric
independent samples, Mann–Whitney U and Kruskal–Wallis
tests were performed, while Wilcoxon Signed Rank test was
performed to test the efficacy of therapy after completion of
treatment course. Chi square test was performed to test for
the difference in the prevalence of the deficient genetic variants
between the COPD and the control groups [34].
Results
Genotyping
The AAT genetic variability testing revealed that, 38 (64%)
subjects were Pi*MM, 11 (19%) Pi*MZ, 3 (5%) Pi*S, 6
(10%) Pi*ZZ and 1 (2%) subject was Pi*Mmalton. A sum-
mary of the genetic variability prevalence among the subjects
of the study is presented in Table 1. There was a statistically
significant difference in the prevalence of the deficient genetic
variants (Pi*MZ, Pi*S, Pi*ZZ and Pi*Mmalton) between the
subjects in the COPD group and those in the control group
(P= 0.0295, Chi Square Test). There were no significant dif-
ferences in the demographic data and the clinical characteris-
tics of the COPD patients and control subjects on
recruitment (Table 2).
The COPD group was further divided according to the
presence or absence of AATD into AAT deficient (patients
with Pi*Mz and Pi*ZZ phenotypes) group (N= 15), and
AAT non-deficient (patients without genetic variability i.e.
Pi*MM) group (N= 15).Table 1 Prevalence of AAT deficiency variants among subjects inc
Variant Control t
N= 29 N
S variant Pi*S 3 (10.7)
Z variant Pi*MZ 2 (6.9)
Pi*ZZ 0 (0.0)
Mmalton Pi*Mmalton 1 (3.4)
Q0Cairo Pi*Q0Cairo NDa
a ND; not done.
b Level of significance at P< 0.05.
c Chi square test.AAT levels in subjects’ plasma
The distribution of AAT level in the COPD group (148.93
± 76.54 mg/dL) was significantly lower than that detected in
the control group (204.67 ± 40.36 mg/dL) (P= 0.0025). By
comparing the AAT level between the genetically deficient
and non-deficient patients, it was found that the AAT level
was significantly lower in the deficient group (81.52
± 47.57 mg/dL) than that recorded in the non-deficient group
(216.35 ± 11.49 mg/dL) (P= 0.0001) (Fig. 1). On further
analysis of the AAT deficient group, it was found that the
Pi*MZ variant had a significantly higher AAT level (117.78
± 15.07 mg/dL) than that found in Pi*ZZ variant (27.12
± 7.32 mg/dL) (P< 0.0001).
Bacterial species isolated from the COPD patients’ sputum
Sputum samples were collected from 28 COPD patients. The
bacterial strains were isolated and identified. Nine samples
yielded no potentially pathogenic bacteria (or only normal
mouth flora), 16 samples resulted in one potentially pathogenic
bacterial species, 2 samples yield two potentially pathogenic
bacterial species, and only one sample had three potentially
pathogenic bacterial species. The isolated microorganisms
included Escherichia coli (39.1%), Bacillus cereus. (17.4%),
Klebsiella pneumoniae (8.7%), Haemophilus influenzae (8.7%),
Acinetobacter baumannii (8.7%), Staphylococcus aureus
(8.7%), Streptococcus pneumoniae (4.3%), and Proteus mir-
abilis (4.3%). Isolated commensals of the oral cavity included
the following: Streptococcus salivarius, Streptococcus parasan-
guinis, and Neisseria macacae. These species were less likely
to be pathogenic and were not included in the counts for bac-
terial loads. Upon enumeration of the potentially pathogenic
bacterial species: 9 samples (32%) had zero bacterial count,
5 samples (18%) had 1.5–8  106, 9 samples (32%) had 1.2–
9  107, and 5 samples (18%) had 2–8  108 CFU/mL.
Detailed information about the identified isolated bacterial
species and their counts is provided in Table S1.
Effect of AAT genetic deficiency on COPD therapeutic outcome
By testing the effect of the genetic variants within the AAT
deficient group between the Pi*MZ and Pi*ZZ variants, no sig-
nificant effect was found on the values of FEV1 (% predicted),
FEV1/FVC6 ratio, FVC6 (% predicted) and 6MWD. But there
was a statistically significant improvement in the values ofluded in the study.
otal
(%)
COPD total
N= 30 N (%)
Pb
0 (0.0) 0.0295c
9 (30.0)
6 (20.0)
0 (0.0)
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Fig. 1 AAT levels in the plasma of the study subjects. The levels
in the plasma of the AAT deficient group (white bar) and AAT
non-deficient group (black bar). The * indicates that the difference
between the two groups is statistically significant as determined by
Independent samples Mann–Whitney U test.
Fig. 2 Distribution of FVC6 throughout the treatment period in
the genetically deficient and non-deficient groups. Forced vital
capacity was measured at three occasions: baseline, 3 months, and
6 months post-initiation of therapy. The AAT-non-deficient group
(white bars) significantly improved compared to the AAT-deficient
group (black bars) at both 3 and 6 months. The * indicates that the
difference between the two groups is statistically significant as
determined by Independent samples Mann–Whitney U test.
Table 2 Demographic and clinical characteristics of study subjects.
Variable Value (N= 59) P*
Patient (N= 30) (range) ‘‘median” Control (N= 29) (range) ‘‘median”
Gender; No. of males (%) 30 (100%) 29 (100%) –
No. of subjects with smoking history (%) 22 ex-smokers (73.33%) 20 ex-smokers (69%) 0.711b
Age (yr) (20–62) ‘‘52” (32–65) ‘‘44” 0.158a
FEV1 (%) (14–53) ‘‘29.5” (58–100) ‘‘86” <0.0001
a
FEV1/FVC6 (%) (36–70) ‘‘59.5” (78–100) ‘‘100” <0.0001
a
FVC6 (%) (22–89) ‘‘52” (57–100) ‘‘86” <0.0001
a
6MWD (m) (185–480) ‘‘347.5” (375–420) ‘‘400” <0.0001a
SPO2 (%) (90–98) ‘‘96” (92–99) ‘‘98” <0.0001
a
AAT level (mg/dL) (17.224–246.992) ‘‘175.56” (101.824–262.28) ‘‘215.89” 0.002a
FEV1: Forced expiratory volume after 1 s.
FVC6: Forced vital capacity.
6MWD: Six minute walk distance.
SPO2: Peripheral capillary oxygen saturation.
AAT: Alpha 1-antitrypsin enzyme.
* Level of significance at P< 0.05.
a Independent samples Mann–Whitney U test.
b Chi-Square test.
AATD and bacterial load in COPD patients 1023FVC6 in the AAT non-deficient group after 3 and 6 months of
treatment (P= 0.0367, P= 0.0112 respectively, independent
samples Mann–Whitney U test) than the AAT deficient group
(Fig. 2) (Table 3). In addition, the SPO2 values were significantly
lower in the AAT-deficient group at baseline (P= 0.036).
Effect of AAT levels on COPD therapeutic outcome
The AAT levels had no significant effect on the values of
FEV1, FEV1/FVC6 ratio and 6MWD. However, the FVC6 val-
ues were significantly lower in the AAT mildly deficient group
at 3 months and 6 months intervals (P= 0.038 and
P= 0.039, respectively) (Fig. 3A). The SPO2 values varied sig-
nificantly among the AAT level groups at baseline, 3 and
6 months (P= 0.043, P= 0.043 and P= 0.049, respectively)
(Fig. 3B) (Table 4).Effect of bacterial loads on COPD therapeutic outcome
Upon investigating the effect of the total bacterial counts on
treatment, it was found that, there was no significant difference
between the 4 groups (0, 106, 107, and 108 CFU/mL) in the
clinical outcomes at baseline, 3 and 6 months intervals. Yet,
in the 106 CFU/mL group, the FEV1/FVC6 ratio varied signif-
icantly after 6 months of treatment (P= 0.043). Also, in the
107 CFU/mL group, the 6MWD test differed significantly after
6 months of treatment (P= 0.025) (Fig. 4). However, in the
108 CFU/mL group there was no significant difference in any
of the clinical parameters before and after treatment.
Fig. 3 Distribution of FVC6 and SPO2 among AAT enzyme level groups. (A) Forced vital capacity and (B) SPO2 were measured on
three occasions: baseline, 3 and 6 months post-initiation of therapy. The parameters’ improvement was monitored in three groups based
on the plasma AAT levels: normal (white bars), mildly deficient (grey bars), and severely deficient (black bars). The * indicates that the
difference between the three groups is statistically significant as determined by independent samples Kruskal–Wallis test.
Table 3 Effect of AAT deficiency on FVC6.
Variable AAT deficient (N= 15) (range) ‘‘median” AAT non-deficient (N= 15) (range) ‘‘median” P*
FVC6 (%) baseline 35–89 ‘‘62” 22–84 ‘‘43” 0.098
a
FVC6 (%) 3 months 40–92 ‘‘65” 19–73 ‘‘46” 0.037
a
FVC6 (%) 6 months 31–96 ‘‘77” 18–77 ‘‘47” 0.011
a
FVC6: Forced vital capacity.
AAT: Alpha 1-antitrypsin enzyme.
* Level of significance at P< 0.05.
a Independent samples Mann–Whitney U test.
Table 4 Effect of AAT levels on therapeutic outcomes of COPD treatment.
Variable Normal AAT (N= 16)
(range) ‘‘median”
Mildly deficient AAT (N= 8)
(range) ‘‘median”
Severely deficient AAT
(N= 6) (range) ‘‘median”
P*
FVC6 (%) Baseline 35–89 ‘‘58” 22–64 ‘‘38.5” 28–84 ‘‘47.5” 0.052
a
FVC6 (%) 3 months 40–92 ‘‘63” 19–71 ‘‘40” 29–73 ‘‘55” 0.038
a
FVC6 (%) 6 months 31–96 ‘‘75” 18–72 ‘‘45” 29–77 ‘‘56” 0.039
a
SPO2 (%) Baseline 94–98 ‘‘97” 91–98 ‘‘96” 90–98 ‘‘93.5” 0.043
a
SPO2 (%) 3 months 95–98 ‘‘96.5” 90–97 ‘‘96” 91–97 ‘‘94” 0.043
a
SPO2 (%) 6 months 96–98 ‘‘97” 90–98 ‘‘96.5” 90–97 ‘‘96” 0.049
a
FVC6: Forced vital capacity.
SPO2: Peripheral capillary oxygen saturation.
AAT: Alpha 1-antitrypsin enzyme.
* Level of significance at P< 0.05.
a Independent samples Kruskal–Wallis test.
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therapeutic outcome
The COPD patients were divided according to the AAT defi-
ciency and the presence or absence of bacterial count into 3groups: group 1 (low risk: non-deficient and zero count,
N= 5), group 2 (moderate risk: non-deficient and the presence
of bacterial count + deficient and zero bacterial count,
N= 12) and group 3 (high risk: deficient and presence of
bacterial count, N= 11). A comparison between the
Table 5 Demographic and clinical characteristics of the groups studied for the combined effect of AATD and bacterial loads.
Variable Group #1 (non-AATD
+ no bacterial load)
(N= 5)
Group #2 (non-AATD+
presence of bacterial load)
and (AATD+ no bacterial
load) (N= 12)
Group #3 (AATD
+ presence of
bacterial load)
(N= 11)
P*
Gender (no. of males) N (%) 5 (100%) 12 (100%) 11 (100%) –
Age (yr) Range 23–60 25–62 44–62 0.265a
Median 40 52.5 55
FEV1 (%) baseline Range 30–37 18–39 14–53 0.315
a
Median 35 27.5 29
FEV1 (%) 6 months Range 35–72 22–77 12–67 0.357
a
Median 41 39.5 32
FEV1/FVC6 baseline Range 41–70 36–69 47–69 0.058
a
Median 58 56.5 65
FEV1/FVC6 6 months Range 59–87 50–99 64–96 0.926
a
Median 73 74 70
FVC6 (%) baseline Range 47–89 28–78 22–84 0.529
a
Median 52 53 43
FVC6 (%) 6 months Range 50–95 31–85 18–77 0.079
a
Median 78 65.5 47
6MWD (m) baseline Range 185–380 200–480 210–410 0.417a
Median 310 350 345
6MWD (m) 6 months Range 210–415 280–600 185–440 0.465a
Median 375 400 380
SPO2 (%) baseline Range 96–98 90–98 91–98 0.051
a
Median 98 96 96
SPO2 (%) 6 months Range 97–98 90–98 90–98 0.170
a
Median 97 97 96
AAT level (mg/dL) Range 200.09–222.82 17.224–246.99 22.728–151.02 0.007a
Median 215.592 212.552 110.12
FEV1: Forced expiratory volume after 1 s.
FVC6: Forced vital capacity, 6MWD: Six minute walk distance.
SPO2: Peripheral capillary oxygen saturation, AAT: Alpha 1-antitrypsin enzyme.
* Level of significance at P< 0.05.
a Independent samples Kruskal–Wallis test.
Fig. 4 Effect of bacterial loads on COPD therapeutic outcomes. Respiratory parameters (A) FEV1/FVC6, (B) 6MWD were measured on
two occasions: baseline (white bars), and 6 months post-initiation of therapy (black bars) among the four groups of bacterial counts. The *
indicates that the difference between the two groups is statistically significant as determined by Wilcoxon signed rank test.
AATD and bacterial load in COPD patients 1025demographic and baseline respiratory parameters is presented
in Table 5, where there was a significant difference in AAT
level among the 3 groups (P= 0.007). Further post hoc anal-
ysis using independent samples Mann–Whitney U test revealeda significant difference between groups 1 and 3 (P= 0.018)
and between groups 2 and 3 (P= 0.034).
Overall, there was no significant difference between the
three groups in the clinical outcomes at baseline, 3 months
1026 M.G. Hennawy et al.and 6 months intervals. However, group 1 showed a significant
improvement after 6 months of treatment in the FEV1
(P= 0.043), FEV1/FVC6 (P= 0.043), FVC6 (P= 0.043)
and 6MWD (P= 0.043, Wilcoxon signed rank test). In addi-
tion, for group 2, there was a significant improvement after
6 months of treatment in the FEV1 (P= 0.004), FEV1/FVC6
(P= 0.013), FVC6 (P= 0.041), 6 MWD (P= 0.003) and
SPO2 (P= 0.026, Wilcoxon signed rank test). On the con-
trary, for group 3, there were no significant improvements
except in the FEV1 (P= 0.037) and FEV1/FVC6 (P= 0.032,
Wilcoxon signed rank test) (Fig. 5A–E).Discussion
AAT deficiency is a genetic disorder that appears in the form
of an early onset pulmonary emphysema, liver cirrhosis and
much less frequently skin disease panniculitis [35]. Studies
showed that 1.9% of COPD patients have AATD [36]. Respi-
ratory failure was reported to be the cause of death in 50–72%
of AATD patients [37]. The risk factors leading to increased
death rates include older age, lower education, smoking, lower
FEV1, lung transplantation, and not receiving augmentation
therapy [38].
In the present study, the normal serum concentration of
AAT ranged between 1.5 and 3.5 g/L (or 20 and 48 lM) [39],
with an average serum AAT level in the COPD group to beFig. 5 Distribution of the respiratory parameters among the combina
parameters (A) FEV1, (B) FEV1/FVC6, (C) FVC6, (D) 6MWD, and (E
6 months post-initiation of therapy (black bars) among the three group
enzyme levels. The * indicates that the difference between the two groups1.489 ± 0.765 g/L. More than 30% of the patients were
belonging to the AAT deficient group. COPD patients having
the Pi*MZ deficiency variant (9/30) were found to be more
prevalent than those having the Pi*ZZ variant (6/30).
A comprehensive survey that was conducted in 2012 in 97
countries (not including Egypt) revealed that, 75% of the
AATD patients had the Pi*MS, while Pi*MZ and Pi*SS vari-
ants were found in 24%. Pi*SZ represented 0.7% and 0.1%
had the Pi*ZZ [40]. Rare deficiency variants prevailed in the
Mediterranean countries. Pi*Mmmalton variant prevailed
over Pi*S and Pi*Z variants in Italy and Central Tunisia
[41], while in Jordan Pi*MS was the most prevalent and Pi*S
was the least prevalent [40]. A controlled study that was con-
ducted on bronchiectasis Egyptian patients revealed the pres-
ence of 1.5% Pi*MZ and 3.5% Pi*SZ deficiency variants
[42]. In the current study, Pi*MZ was the most common defi-
cient variant while Pi*S was the least.
Pathogenic bacteria cause a significant proportion of acute
exacerbations of COPD and it was found that half COPD
exacerbations were attributed to bacterial infections [18,43].
In a study conducted by Wilkinson et al., it was observed that
the increase in airway bacterial loads was associated with
greater airway inflammation and accelerated decline in FEV1
[44].
The present study – looking into the effect of the AAT,
either genetically or biochemically – indicated that, the
non-deficient group showed significant improvement over thetion of bacterial loads and AAT enzyme levels groups. Respiratory
) SPO2 were measured on two occasions: baseline (white bars), and
s based on the combination between the bacterial loads and AAT
is statistically significant as determined byWilcoxon signed rank test.
AATD and bacterial load in COPD patients 1027deficient ones in few parameters namely FVC6 and the
SPO2. On the other hand, when AATD was combined with
bacterial loads, a much greater impact was observed in the
responsiveness of COPD patients to treatment, where the
low-risk group showed a significant improvement in almost
all the measured parameters (FEV1, FEV1/FVC6, FVC6,
and 6MWD). However, the high-risk group only showed
improvement in the FEV1 and FEV1/FVC6 indicating, for
the first time, that the combination of AATD and bacterial
loads had a significant impact on the therapeutic outcome of
COPD treatment.Conclusions
The findings of the current pilot study represent a starting
point for further investigations of the role of AATD and bac-
terial load combination on COPD treatment in the Egyptian
population. The significance of these findings stems from the
opportunity that can be created by decreasing the bacterial
loads in the lungs of COPD patients especially those with
AAT-deficiency, at the beginning of any pharmacological
treatment. Those patients are predicted to respond much better
to treatment than those receiving treatment while keeping the
bacterial loads high.Study limitations
The small sample size is the main limitation of this study. This
is attributed to the difficulty in recruiting patients with the pre-
viously set inclusion and exclusion criteria from Cairo Univer-
sity hospitals, because the treatment in Cairo University
hospitals is a completely free service, so priority in the provi-
sion of care is always given to critical patients suffering from
multiple complications.Conﬂict of interest
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